Trial Profile
A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Elosulfase alfa (Primary)
- Indications Mucopolysaccharidosis IV
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 07 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Oct 2014 New trial record